Preventing stroke in atrial fibrillation: the SPORTIF programme

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Background:

• Atrial fibrillation (AF) is a primary risk factor for stroke.
• Warfarin, a vitamin K antagonist, is effective but has significant limitations including monitoring needs and drug interactions.
• A need exists for safer, more convenient anticoagulation options in AF management.

Purpose of the Study:

• To evaluate the efficacy and safety of ximelagatran, an oral direct thrombin inhibitor, compared to warfarin for stroke prevention in AF.
• To assess ximelagatran's fixed-dose regimen and lack of coagulation monitoring against warfarin's variable dosing and monitoring requirements.

Main Methods:

• The Stroke Prevention using an ORal direct Thrombin Inhibitor in atrial Fibrillation (SPORTIF) III and V trials enrolled over 7,000 moderate- to high-risk AF patients.
• Ximelagatran (36 mg twice daily) was compared to well-controlled warfarin (INR 2.0-3.0).
• Efficacy endpoints included stroke and systemic embolic events; safety endpoints focused on major bleeding events.

Main Results:

• SPORTIF III showed a numerically lower rate of stroke and systemic embolic events with ximelagatran versus warfarin (1.6% vs. 2.3% per year).
• Preliminary SPORTIF V data suggest non-inferiority of ximelagatran compared to warfarin.
• Both trials indicated a trend towards lower major and minor bleeding rates with ximelagatran.

Conclusions:

• Fixed-dose ximelagatran is comparable to dose-adjusted warfarin in preventing thromboembolic events in moderate- to high-risk AF patients.
• Ximelagatran offers a favorable safety profile with reduced bleeding risk and eliminates the need for coagulation monitoring.
• Ximelagatran's profile may broaden anticoagulation eligibility and improve stroke prevention in AF.